Teresa Alonso‐Gordoa

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Enrique Grande, Jaume Capdevila, Daniel Castellano et al. · Annals of Oncology · 2015 · 155 citations · Full text

Open-label Trial, Endocrine Oncology, Surgical Oncology +10

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 126 citations · Full text

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason et al. · Journal of Clinical Oncology · 2021 · 122 citations · Full text

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Ángela Lamarca et al. · Journal of Clinical Oncology · 2019 · 69 citations · Full text

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

Jaume Capdevila, Jorge Hernando, Àlex Teulé et al. · Nature Communications · 2023 · 46 citations · Full text